

Acute Treatment for Migraine

Author: Rachelle Davis, PharmD

Executive Summary

Acute treatment for migraines should be individualized to each patient and consider the individual characteristics of the patient's migraines. Use of OTC agents and prescription NSAIDs should be recommended for less severe migraines. Adverse effects often limit the use of select agents, mainly cardiovascular effects that preclude use of triptans and ergotamines. Caution should be used to avoid risk of medication overuse headache.

All patients with a migraine should be offered a trial of acute treatment. The individual characteristics of migraine headaches should be taken into consideration, such as intensity, presence of nausea/vomiting, onset of pain, and duration of pain, when developing treatment plans for your individual patient.

Acronyms	
CAD	Coronary artery disease
CGRP	Calcitonin gene-related peptide
DHE	Dihydroergotamine
IM	Intramuscular
NSAID	Nonsteroidal anti-inflammatory drugs
OTC	Over the counter
PVD	Peripheral vascular dysfunction

Table 1: Migraine Treatments

Mild-moderate migraine	Moderate-severe migraine, or mild-moderate that responded poorly to initial treatment
- Non-opioid analgesics - NSAIDs - Caffeinated analgesic combinations	- Triptans - Ergotamine derivatives - Antiemetics - Serotonin 5-HT_{1f} agonist (lasmiditan) - CGRP receptor blockers (discussed in detail on a separate but related document)

Pearls for Selecting Abortive Therapy

- Choose a non-oral route of administration for severe nausea or vomiting
- Account for tolerability and safety issues
 - NSAID risk for gastrointestinal and cardiovascular side effects
 - Triptans and DHE should be avoided or used with caution in patients with CAD, PVD, uncontrolled hypertension and stroke
 - Lasmiditan may cause fatigue, lethargy, and somnolence, patients should not drive or operate machinery for 8 hours after a dose
- Take into consideration the tempo of headache pain escalation
 - For migraine headaches that escalate in intensity very rapidly, or that are fully developed upon awakening:
 - Subcutaneous sumatriptan is the most effective
 - Other medications to consider include rizatriptan, eletriptan, nasal sumatriptan or nasal zolmitriptan
 - For less severe attacks that build up more slowly but have a relatively long duration:
 - Choose longer-acting options such as naproxen and/or frovatriptan

4. Consider self-administered rescue
 - a. Patients may require rescue medication when first-line acute treatment does not bring relief
 - b. Choice of rescue agent depends on initial treatment, options include:
 - i. SubQ sumatriptan
 - ii. DHE injection or intranasal spray
 - iii. Dexamethasone
 - iv. IM ketorolac
 - c. Consider prescribing in patients with severe attacks and those with a history of nonresponse/variable response to acute treatment
5. Combination therapy
 - a. Using agents together is often more efficacious than using them as monotherapy
 - b. Triptans, NSAIDs and antiemetics are commonly used as part of combination therapy
 - c. Antiemetics can improve absorption, and therefore improve effectiveness of triptans and NSAIDs
 - d. Triptans and lasmiditan have similar mechanisms of action and should avoid combination use together until more information is available
 - e. Triptans and ergotamines should not be used within 24 hours of each other due to additive vasoconstrictive effects
6. Avoid medication overuse
 - a. Limit acute treatment to an average of two headache days per week
 - i. Offer preventive treatment to those exceeding this limit
 - ii. Patients who exceed this limit despite use of preventive treatment may require:
 1. Escalation in dose
 2. Change in preventive therapy, or
 3. Addition of another preventive treatment
7. Opioids and barbiturates
 - a. Although can be effective for acute treatment of migraines, use of opioids and barbiturates (e.g., butalbital) are not recommended as first line or for long-term use as they are habit forming and contribute to medication overuse headache and chronic migraine
 - b. Opioids can be considered as a last resort in patients who have contraindications to or fail migraine-specific treatments
 - i. Limit to nine days per month or less to avoid medication overuse headache
 - ii. Continue to focus on preventive and behavioral aspects of migraine care

Table 2: Drugs for Acute Treatment of Migraines

Drug class	Drug names	Pearls
Non-opioid analgesics	- Aspirin - Acetaminophen - Aspirin/acetaminophen/caffeine	Effervescent aspirin has a faster onset than oral tablets
NSAIDs	- Diclofenac - Ibuprofen - Naproxen - Ketorolac nasal spray	Diclofenac powder for oral solution and ketorolac nasal spray have a faster onset of action than oral tablets (both significantly more expensive than tablet/capsule)
Triptans	- Almotriptan - Naratriptan - Frovatriptan	- Differ by onset of action, duration of action, route of administration, and cost - Failure with one triptan does not predict failure with another

	- Sumatriptan – tablets, nasal spray, nasal powder, and SubQ injection - Sumatriptan/naproxen - Rizatriptan - Eletriptan - Zolmitriptan – tablets, nasal spray	Strong vasoconstricting effects caused by activation of serotonin receptor 1B
Ergotamine derivatives	- Ergotamine sublingual - Caffeine/ergotamine - Dihydroergotamine IM, SC, nasal spray	- Significant nausea and vomiting limit use – use antiemetics - Strong vasoconstricting effects result in cardiovascular adverse effects
Antiemetics	- Metoclopramide - Prochlorperazine - Promethazine	- Take at onset of migraine - Efficacy in treating acute migraine even in the absence of nausea and vomiting - Serotonin antagonist antiemetics (e.g., ondansetron) are not effective for migraine headache pain
Serotonin 5-HT _{1F} receptor agonist	Lasmiditan (Reyvow)	- No vasoconstricting serotonin effects as seen with triptans - Schedule IV controlled substance - Can be used in patients at high cardiovascular risk - Avoid in severe hepatic impairment

References

- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18.
- Langer-Gould AM, Anderson WE, Armstrong MJ, et al. The American Academy of Neurology's top five choosing wisely recommendations. Neurology 2013. Available at <https://pdfs.semanticscholar.org/6e16/123231bb60600d512fdff35548f38bd440d.pdf>. Accessed September 7, 2021.
- Ong JJ, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics 2018;15:274-90.

Document Owner: Pharmacy Pearls Steering Committee

Date of Review: 10/28/21, 2/16/23

Review Committee Leaders: Becky Vande Kop, MD, Clinical Vice President, Primary Care Service Line; Chad Thury, DO, Chair, Primary Care Service Line Quality Subcommittee

Content Author: R. Davis, PharmD

Last updated: 2/27/24 | Page 3

Migraine Prevention

Author: Rachelle Davis, PharmD

Executive Summary

Migraine prophylactic treatment should be considered in patients who are experiencing or at risk for medication overuse headaches, experiencing multiple migraines or migraine days per month, have difficulty tolerating acute therapy or have certain migraine subtypes.

A combination of lifestyle management and pharmacotherapy

should be employed to reduce migraine frequency. Remember to titrate prophylactic agents every two to four weeks and consider a combination of agents or a second-line agent if initial therapy is not efficacious.

Acronyms	
BID	"Bis in die" – Two days a day
CGRP	Calcitonin gene-related peptide
TID	"Ter in die" – Three times a day

Migraines can be triggered by a variety of things and are specific to individual patients. Identification of an individual's triggers can be aided by things like suggesting the use of a headache diary. Once triggers are identified, symptoms may be managed by avoidance of triggers or treatment of underlying conditions.

Common Migraine Triggers

- Additives
- Alcohol
- Artificial sweeteners
- Caffeine (overconsumption or withdrawals)
- Exercise
- Foods
- Light
- Menses
- Missed or delayed meals
- Odors
- Oral contraceptives
- Red wine
- Sleep disturbances
- Smoke
- Stress
- Weather changes

Considerations for Starting Prophylactic Treatment:

- Four or more headaches a month or at least eight headache days a month
- Debilitating attacks despite appropriate acute management
- Difficulty tolerating or having a contraindication to acute therapy
- Medication-overuse headache
- Patient preference
- Presence of certain migraine subtypes (i.e., hemiplegic migraine; migraine with brainstem aura; migrainous infarction; or frequent, persistent or uncomfortable aura symptoms)

There are a variety of medications that have varying levels of evidence for efficacy. Included on the table below are medications with the best evidence of efficacy. Not included are CGRP agents that can be used for migraine prevention, which are addressed on a separate but related document.

Table 1: Recommended Medications for Episodic Migraine Prevention

First-Line Agents	Initial dose	Maximum dose
Divalproex/Valproic acid	500mg PO daily	1000mg/day
Metoprolol tartrate	25mg PO BID	200mg/day
Propranolol	40-80mg/day PO	160mg/day
Timolol	10mg PO BID	30mg/day
Topiramate	25mg PO daily	100mg/day
Frovatriptan*	2.5mg PO daily	2.5mg PO BID
Second-Line Agents	Initial dose	Maximum dose
Amitriptyline	10-25mg/day PO	150mg/day
Atenolol	25mg PO daily	100mg daily
Nadolol	20mg PO daily	240mg/day
Venlafaxine ER	37.5mg PO daily	75-150mg/day
Naratriptan*	1mg PO BID	5mg/daily
Zolmitriptan*	2.5mg PO BID	2.5mg TID

*Efficacious for short-term prevention of menstrual associated migraine. Dosed starting two days prior to onset of menses and continued through to five days after the onset of menses (seven days total).

In 2012 the American Academy of Neurology and the American Headache Society provided an update to the 2000 guidelines for migraine prevention. The original guideline concluded that calcium channel blockers were probably effective, but were later found to have conflicting evidence on the basis of the current classification criteria and thus the recommendation was downgraded to a Level U (evidence is conflicting or inadequate to support or refute the use for migraine prevention).

Additionally, onabotulinumtoxinA (Botox) has FDA approval for prophylaxis of chronic migraine (15 or more headache days per month). Clinical trials showed clinically significant reduction in frequency of headache days compared to placebo relative to baseline. Study results have been mixed in prevention of episodic migraine (14 or less headache days per month) and does not have FDA approval for this indication.

Medications should be initiated at the lowest dose and be titrated every two to four weeks until effective. Maximal efficacy may take up to six months. A different medication can be considered after two months if it is not efficacious, or side effects are not well tolerated. A different first-line agent should be trialed or a combination of first-line agents. If continued treatment failure, a second-line agent should be considered.

Although there is data to support use of pharmacological treatment for migraine prevention, there is not enough data to establish how to choose optimal therapy or to support the use of one first line option over another. **Regimens should be prescribed on a case-to-case basis taking into account efficacy, adverse effects, comorbidities and personal considerations. Trial and error are often required.**

Special populations

- **Children:** There are currently no approved medications with proven efficacy for migraine prevention in children. Topiramate and propranolol have shown conflicting results in studies and other commonly prescribed medications such as cyproheptadine, amitriptyline, and valproic acid lack sufficient data in children.
- **Pregnancy:** Nonpharmacological treatment options should be explored prior to initiating drug therapy. Preventive medications may have teratogenic effects. If treatment is absolutely necessary, select a treatment with the lowest risk of adverse effects to the fetus.

References

- Silberstein S. D. (2015). Preventive Migraine Treatment. *Continuum (Minneapolis, Minn.)*, 21(4 Headache), 973–989.
<https://doi.org/10.1212/CON.0000000000000199>
- Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Erratum in: *Neurology*. 2013 Feb 26;80(9):871. PMID: 22529202; PMCID: PMC3335452.
- Ha H, Gonzalez A. Migraine Headache Prophylaxis. *Am Fam Physician*. 2019 Jan 1;99(1):17-24. PMID: 30600979.
- Silberstein SD. Headaches in pregnancy. *J Headache Pain*. 2005;6(4):172–174.
- Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache*. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7. PMID: 20487038.
- Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010 Jul;30(7):804-14. doi: 10.1177/0333102410364677. Epub 2010 Mar 17. PMID: 20647171.
- Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburg AM; BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. *Headache*. 2007 Apr;47(4):486-99. doi: 10.1111/j.1526-4610.2006.00624.x. PMID: 17445098.

Document Owner: Pharmacy Pearls Steering Committee

Date of Review: 10/28/21, 2/16/23

Review Committee Leaders: Becky Vande Kop, MD, Clinical Vice President, Primary Care Service Line; Chad Thury, DO, Chair, Primary Care Service Line Quality Subcommittee

Calcitonin Gene-Related Peptide Receptor Antagonist Overview

Author: Rachelle Davis, PharmD

Executive Summary

CGRP is a naturally occurring neuropeptide associated with migraines. CGRP antagonists are a newer class of medications that may be used for preventative or abortive therapy in migraine patients. CGRP-related therapies have proven efficacy, safety, and tolerability for migraine prevention and treatment in phase II and phase III randomized, placebo-controlled clinical trials. Benefits of

CGRP-related therapies include minimal adverse effects, easy dosing, and rapid efficacy; however, this should be weighed against the cost (addressed separately) and lack of head-to-head efficacy data on other treatment modalities.

Acronyms	
CGRP	Calcitonin gene-related peptide
CYP3A4	Cytochrome P450 3A4
ESRD	End-stage renal disease
HTN	Hypertension

CGRP occurs naturally in the central and peripheral nervous system and acts as a potent vasodilator. Levels increase during a migraine and is believed to be directly involved in pathophysiologic processes underlying migraines. CGRP causes a cascade of events contributing to neurogenic inflammation, including mast-cell degranulation, vasodilation and protein extravasation when bound to its receptor. CGRP antagonists block the release of CGRP at all migraine pathway locations and prevent vasodilation and neurogenic inflammation.¹ In this way, they act to prevent migraine headaches.

Large molecule monoclonal antibodies acting as CGRP ligand antagonists, such as fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti), bind to CGRP ligands and block its ability to bind to its receptor. Erenumab (Aimovig), a CGRP receptor antagonist monoclonal antibody, binds to the receptor site and antagonizes the receptor's function. These large molecule agents effectively prevent migraine headaches.² There is no evidence that supports one mechanism of action is superior to another (ligand antagonists vs receptor antagonist). Atogepant (Qulipta), Rimegepant (Nurtec), ubrogepant (Ubrelvy) and zavegapant (Zavzpret) are small molecule CGRP receptor antagonists which can provide acute relief or prevention of migraines.

Efficacy Summary:

- Migraine prophylaxis: Prophylactic agents reduced the number of migraine days per month compared to placebo (1-3.5 migraine days per month reduction vs placebo) and increased the number of patients experiencing a 50% reduction in monthly migraine days compared to placebo (10-25% more patients vs placebo).
- Acute migraine treatment: Agents with the indication for acute treatment have demonstrated improvement in the proportion of patients pain-free at two hours, with 7.5-10% more patients' pain free compared to placebo. There was also improvement in most bothersome symptom freedom at two hours, with around 10% more patients experiencing symptom freedom when compared to placebo.

Clinical Pearls:

- Target the trigeminal pain system; therefore, this class of medication is more specific and causes far fewer adverse effects than traditional migraine preventative agents.³
- Do not constrict blood vessels, unlike other first-line therapies for migraine, so these agents may be useful in patients with cardiovascular contraindications³
- The agents approved for prophylactic use (excluding rimegepant and atogepant) lack hepatic and renal metabolism and clearance, so there are no drug interactions with concomitant medications³
- Prophylactic agents do not require dose titrations, demonstrate rapid effects in treatment and are effective in patients who have failed prior preventive treatment³

- There is theoretical concern for cardiac side effects because they antagonize CGRP, which is a vasodilator. Studies to date have not shown cardiovascular effects; however, most have excluded patients with significant cardiovascular risk factors.^{4,5}
- CGRP antagonists can be combined with non-CGRP oral agents.^{4,5}
- Data is lacking regarding combined use of CGRP antagonists for both prophylaxis and acute treatment.^{4,5}
- Data is lacking on the comparative efficacy between CGRP antagonists and other prophylactic therapies; however, as concluded from a systematic review and meta-analysis, triptan drugs were shown to be significantly more efficacious compared with CGRP antagonists, such as rimegepant, in the treatment of migraine headaches with or without aura in adult patients for pain freedom two hours after dosing and pain relief.⁶
- Subcutaneous injections: Hypersensitivity reactions may occur. Counsel patients regarding signs of anaphylaxis and angioedema and what to do if they experience these reactions.
- Fetal harm was observed in animal studies with Nurtec, Ubrelvy, Qulipta and Reyvow. Little data is available for Aimovig, Ajovy, Emgality, Vyepti or Zavzpret. It is not known if any CGRP antagonist agents are present in breastmilk.

Table 1: CGRP Therapy Pearls

Drug	Place in Therapy	Pearls for Use
Erenumab (Aimovig)	Migraine prophylaxis	• Do not use if latex allergy • Monitor for new or worsening HTN • Severe constipation may occur • Patient may self-administer subQ injection
Fremanezumab (Ajovy)	Migraine prophylaxis	• Patient may self-administer subQ injection
Galcanzumab (Emgality)	Migraine prophylaxis	• Patient may self-administer subQ injection
	Episodic cluster headache	
Eptinezumab (Vyepti)	Migraine prophylaxis	• Common side effects include nasopharyngitis • Administer via IV infusion only
Atogepant (Qulipta)	Migraine prophylaxis	• Common side effects include constipation, nausea and fatigue • May take with or without food • Avoid use in severe hepatic impairment • Avoid use in ESRD in patients with chronic migraines • Avoid use with strong CYP3A4 inhibitors
Rimegepant (Nurtec [ODT])	Migraine prophylaxis	• Common side effects include abdominal pain, indigestion and nausea • Open blister pack with dry hands. Do not push the tablet through the foil • Let dissolve completely on/under tongue (should dissolve within a few seconds) • Avoid use in ESRD • Avoid use in severe hepatic impairment • Drug interactions with CYP3A4 inhibitors, avoid strong inhibitors
	Acute migraine treatment with or without aura	
Ubrogepant (Ubrelvy)	Acute migraine treatment with or without aura	• Common side effects include nausea, sedation and dry mouth • A second dose may be taken at least two hours after initial dose if needed • Oral administration • Avoid grapefruit juice • Contraindicated with strong CYP3A4 inhibitors

Zavegepant (Zavzpret)	Acute migraine treatment with or without aura	• Common side effects include altered taste, nausea/vomiting and nasal irritation • Intranasal administration • Avoid use in ESRD • Avoid use in severe hepatic impairment
----------------------------------	---	---

Cluster Headache: often misdiagnosed as migraine; most common of the primary headache disorders (“trigeminal autonomic cephalalgias”); attacks occur in cyclical patterns, or clusters²

Resources:

[AMG Guideline – CGRP Antagonist Medications for Episodic & Chronic Migraines](#)

References

Harvey P, Shah P, Shipley S. An overview of new biologics for migraine prophylaxis. *US Pharm*. 2020;45(1):21-24.

Peters GL. Migraine overview and summary of current and emerging treatment options. *Am J Manag Care*. 2019;25:-S0. Available at: <https://www.ajmc.com/view/migraine-overview-and-summary--of-current-and-emerging-treatment-options>.

American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59:1-18.

Clinical Resource, Drugs to prevent migraine in adults. Pharmacist’s Letter/Prescriber’s Letter. November 2020.

Clinical Resource, Comparison of triptans and other drugs for acute migraine. Pharmacist’s Letter/Prescriber’s Letter. March 2020.

Ha DK, Kim MJ, Han N, et al: Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: updated meta-analysis. *Clin Drug Investig* 2021; 41(2):119-132.

Document Owner: Pharmacy Pearls Steering Committee

Date of Review: 10/28/21, 2/16/23

Review Committee Leaders: Becky Vande Kop, MD, Clinical Vice President, Primary Care Service Line; Chad Thury, DO, Chair, Primary Care Service Line Quality Subcommittee

CGRP Use: Cost and Avera Health Plans Utilization

Author: Rachelle Davis, PharmD

Executive Summary

Oral and injectable calcitonin gene-related peptide receptor (CGRP) antagonists and inhibitors are safe and effective agents for treating and preventing migraines. However, these agents come at a substantial cost relative to alternative drug classes without providing clear additive benefits. In addition, no phase 3/4 clinical trials exist that demonstrate additive efficacy of combined preventive and abortive CGRP inhibition. As a result, several utilization management strategies have been put in place by third-party payers including step-therapy, prior authorization, quantity limits and network restriction.

Table 1: Abortive Migraine Agents

Drug [generic] (Drug Class)	Quantity Limit (30 days)	Approximate Cost (30 days)
Ubelvly [ubrogepant] (CGRP antagonist)	12 tablets	\$1,200
Nurtec ODT [rimegepant] (CGRP antagonist)	8 tablets	\$1,200
Zavzpret [zavegepant] (CGRP antagonist)	6 sprays	\$1,300
Reyvow [lasmiditan] (serotonin 5-HT _{1F} antagonist)	8 tablets	\$800
Sumatriptan 25mg, 50mg (triptan)	18 tablets	\$4
Sumatriptan 100mg (triptan)	9 tablets	\$7
Naratriptan 1 mg (triptan)	18 tablets	\$29
Zolmitriptan 2.5mg (triptan)	12 tablets	\$90
Zolmitriptan 5mg (triptan)	6 tablets	\$45
Rizatriptan 5mg (triptan)	24 tablets	\$14
Rizatriptan 10mg (triptan)	12 tablets	\$29
Frovatriptan (triptan)	18 tablets	\$1,000
Eletriptan 20mg (triptan)	12 tablets	\$250
Eletriptan 40mg (triptan)	6 tablets	\$100
Fioricet [butalbital, acetaminophen, and caffeine] (barbiturate, non-opioid analgesic)	180 tablets	\$26

Table 2: Preventive Migraine Agents

Drug [generic] (Drug Class)	Approximate Cost (30 days)	Comments
Ajovy [fremanezumab] (CGRP antagonist)	\$750	
Aimovig [erenumab] (CGRP antagonist)	\$750	
Emgality [galcanezumab] (CGRP antagonist)	\$750	
Vyepti [eptinezumab] (CGRP antagonist)	\$600	Medical benefit drug. Given via IV infusion (cost does not reflect costs associated with infusion).
Nurtec ODT [rimegepant] (CGRP antagonist)	\$1,900 (quantity limit 15 tablets/30 days)	Approved for episodic migraine only (≤ 14 migraines/month)
Qulipta (atogepant) (CGRP antagonist)	\$1,300	Approved for episodic or chronic migraines

Propranolol ER (beta-blocker)	\$60	
Amitriptyline (tricyclic antidepressant)	\$7	
Valproate ER (anticonvulsant)	\$25	
Topiramate (anticonvulsant)	\$2	

Combination of Abortive and Preventive CGRP Inhibitors

A phase 1b clinical trial, a two-patient case study and a currently unpublished abstract presented at the 2021 American Headache Society Annual Scientific Meeting have evaluated the use of combination injectable/oral CGRPs.¹⁻³ These studies have shown that combination use is safe with no increase in adverse effects and no significant pharmacokinetic drug interactions. However, no randomized prospective data is available to evaluate the efficacy of combined oral/injectable CGRP use at this time.

Avera Health Plans Prior Authorization Criteria (Chronic Migraine Prevention)

CGRPs for Migraine Prevention (Aimovig, Ajovy, Emgality, Vyepti, and Qulipta)

1. Patient must be 18 years of age or older
2. Member has 15 or more headaches lasting four hours or more in a 28-day period (50% or more of these headaches must be migraine/probably migraine in nature).
3. First migraine episode occurred six months or longer ago.
4. Member must have failed at least one previous self-administered preventative CGRP antagonist agent prior to eptinezumab-jjmr approval.
5. Patient must have a treatment failure, intolerance, or contraindication to two migraine prophylactic medication classes:
 - a. Antidepressants
 - b. Anti-epileptic agents
 - c. Beta-blockers/calcium channel blockers
6. Patient is not on concurrent Botox therapy for migraine prevention.
7. Member is not receiving atogepant, rimegepant, ubrogepant, lasmiditan, or zavegepant.
8. Dose does not exceed FDA-approved dosage.

Additional Utilization Management Criteria

All self-injectable CGRPs antagonists (Aimovig, Ajovy, and Emgality) are considered specialty drugs restricted to dispensation by the Avera Health Plan Specialty Pharmacy Network. No more than a 30-day supply of medication may be dispensed at any time (with the exception of every three-month dosing regimens).

Botox

Approved only for prevention of chronic migraine and can be used in combination with an abortive CGRP antagonist. Avera Health Plan's Botox prior authorization criteria is similar to that of the preventive CGRP antagonist criteria.

References

- Tolbeyan AS, et al. CGRP monoclonal antibodies along with CGRP receptor antagonists are safe and effective together and compared to standard of care. Abstract P-155. American Headache Society Annual Scientific Meeting. June 3-6, 2021. <https://doi.org/10.1111/head.14130>
- Mullin K, et al. 2020. Potential for Treatment Benefit of Small Molecule CGRP Receptor Antagonist Plus Monoclonal Antibody in Migraine Therapy. *Neurology*. 2020; 00: 1-5. doi: 10.1212/WNL.0000000000008944
- Kakete et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. *Headache*. 2021; 61:642-652. doi: 10.1111/head.14095

Document Owner: Pharmacy Pearls Steering Committee

Date of Review: 10/28/21, 2/16/23

Review Committee Leaders: Becky Vande Kop, MD, Clinical Vice President, Primary Care Service Line; Chad Thury, DO, Chair, Primary Care Service Line Quality Subcommittee